We set out three years ago to jumpstart progress toward a cure for Alzheimer’s disease and we are succeeding.
- The Alzheimer’s Genome Project™ (AGP), targeting the full set of Alzheimer’s genetic risk factors, identified seventy new genes, a tremendous result and truly breakthrough research.New genes open extensive novel scientific avenues for better understanding the disease and development of effective therapies.
- Publications announcing these results have begun and findings will continue to be announced in coming months.
- Other funded work, such as the AlzGene tool which allows researchers around the world to share and analyze information, is driving progress forward in unprecedented ways.
The personal and economic impact of Alzheimer’s is enormous and the path to a cure is through research.
When we first met with Dr. Rudy Tanzi to discuss Cure Alzheimer's Fund, we asked him two things:
Can you recruit a group of first-class Alzheimer’s researchers to guide us in our investment in basic research into the causes of the disease?
What is the most important first step we can take to truly make a difference?
Dr. Tanzi answered the first question by assembling the group of researchers known as the Cure Alzheimer’s Fund Research Consortium. They answered the second question thusly: find all the genes that contribute to risk for Alzheimer’s disease.
Dr. Tanzi estimated that task would take about three years and about $3 million. He was right.
With the holidays approaching and the conclusion of 3 years of progress at Cure Alzheimer’s Fund, we are grateful for your support and excited about the challenges ahead.
The Progress. We are funding 17 research projects in 8 different outstanding research institutions across the nation.
First, a hearty thank you to all of you who have supported us. Your money has been put to good use. The first operating year of Cure Alzheimer’s Fund has been most gratifying for the founders, donors, researchers --- all of us committed to doing what we can to end the scourge of Alzheimer’s disease in our lifetime.
Henry McCance, Founding Board Member
Henry McCance is a Founding Board member of Cure Alzheimer’s Fund and Chairman of Greylock Partners, a leading venture capital firm with a distinguished and highly successful record of company building. His family situation brought him to this effort as his words describe here.
To capitalize on this rare “science moment” as Rudy (Tanzi) calls it, we are committed to focused, disciplined funding of targeted research which we refer to as the Venture approach. All of our Founders have strong business backgrounds, and two of us are long-time venture capitalists. We have all made careers from betting on people who rose to excellence and on providing the best resources available to help them achieve their potential. That is the approach we are bringing to Cure Alzheimer’s Fund.
Jeffrey Morby, Chairman, Cure Alzheimer's Fund
Welcome to the Cure Alzheimer's Fund website. This is an auspicious time for accelerating Alzheimer's disease research. More of us unfortunately are touched by this disease as friends, relatives and associates are afflicted. Additionally, as the "boomers" enter the most dangerous Alzheimer's age range (60+), we threaten to swamp our already fragile healthcare system.
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.